SureTrader SureTrader
Home > Boards > US Listed > Biotechs > Arena Pharmaceuticals, Inc. (ARNA)

orexigen is no compensation at this point whatsoever period.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
lovethatgreen Member Profile
Member Level 
Followed By 213
Posts 22,748
Boards Moderated 1
Alias Born 08/07/04
160x600 placeholder
Advertisement
Arena Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference "PR Newswire (US)" - 5/26/2015 8:00:00 AM
Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker "The Motley Fool" - 5/16/2015 11:04:02 AM
Which of These Growth Stocks Is Most Worthy of Your Money? "The Motley Fool" - 5/16/2015 10:02:02 AM
Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at Upcoming Medical Meetings "PR Newswire (US)" - 5/14/2015 8:00:00 AM
Why Shares of Orexigen Therapeutics, Inc. Cratered Today "The Motley Fool" - 5/13/2015 11:48:02 AM
Orexigen Terminates Required Study for Diet Drug Contrave "Dow Jones News" - 5/12/2015 5:05:54 PM
Why It's Lights Out for Orexigen Therapeutics, Inc. "The Motley Fool" - 5/12/2015 3:24:10 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/11/2015 5:44:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/11/2015 4:22:25 PM
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2015 Financial Results "PR Newswire (US)" - 5/11/2015 4:07:00 PM
Arena Pharmaceuticals and Roivant Sciences Enter into Collaboration for Nelotanserin, a Novel Inverse Agonist of the 5-HT2A R... "PR Newswire (US)" - 5/11/2015 4:01:00 PM
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference "PR Newswire (US)" - 5/8/2015 8:00:00 AM
Arena Pharmaceuticals to Host First Quarter 2015 Financial Results Conference Call and Webcast on Monday, May 11 "PR Newswire (US)" - 5/7/2015 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 4/30/2015 1:11:57 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 4/29/2015 4:26:56 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 4/29/2015 4:24:19 PM
Arena Pharmaceuticals Reports Favorable Results from Phase 1 Single-Ascending Dose Clinical Trial of APD371 "PR Newswire (US)" - 4/29/2015 8:00:00 AM
Arena Pharmaceuticals Inc.'s Plan to Win the Obesity Drug War "The Motley Fool" - 4/24/2015 8:10:02 AM
3 Promising Small-Caps Under $10 You Can Buy Right Now "The Motley Fool" - 4/21/2015 9:06:02 AM
3 Promising Healthcare Stocks Under $10 "The Motley Fool" - 4/15/2015 8:02:02 AM
Arena's 15,000 Scripts Set Pace Vs. Competitors "Seeking Alpha" - 4/13/2015 11:00:47 AM
Orexigen: Contrave Scripts Dip - Were My Concerns About Advertising Right? "Seeking Alpha" - 4/13/2015 10:23:41 AM
Arena Gets Closer On Extended Release Formulation Of Belviq "Seeking Alpha" - 4/13/2015 7:59:01 AM
The Best Stock to Invest in Obesity Drugs "The Motley Fool" - 4/12/2015 2:03:03 PM
Arena's Partner Eisai Is Slashing Jobs - What Investors Need To Consider "Seeking Alpha" - 4/10/2015 10:27:12 AM
lovethatgreen Member Level  Monday, 05/14/12 08:57:20 AM
Re: gixxer11 post# 4348
Post # of 21912 
orexigen is no compensation at this point whatsoever period.

and vvus at the stage theyre at, is at a disadvantage in several ways

no manufacturing set up....the risks with the drug are numerous combined with detox requirements after 90 days

I could go on

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist